The function of PI3K-mTOR pathway in regulating NK cell improvement has been extensively reported. However, it stays unclear whether or not NK cell improvement depends upon the protein kinase B (PKB), which hyperlinks PI3K and mTOR, maybe because of the potential redundancy of PKB. PKB has two phosphorylation websites, threonine 308 (T308) and serine 473 (S473), which may be phosphorylated by phosphoinositide-dependent protein kinase-1 (PDK1) and mTORC2, respectively. In this research, we established a mouse mannequin wherein PKB was inactivated by the deletion of PDK1 and Rictor, a key element of mTORC2, respectively.
We discovered that the only deletion of PDK1 or Rictor may result in a major defect in NK cell improvement, whereas mixed deletion of PDK1 and Rictor severely hindered NK cell improvement on the early stage. Notably, ectopic expression of myristoylated PKB considerably rescued this defect. In phrases of mechanism, in PDK1/Rictor-deficient NK cells, E4BP4, a transcription issue for NK cell improvement, was much less expressed, and the exogenous provide of E4BP4 may alleviate the developmental defect of NK cell in these mice. Besides, overexpression of Bcl-2 additionally helped the survival of PDK1/Rictor-deficient NK cells, suggesting an anti-apoptotic function of PKB in NK cells.
Natural killer (NK) cells and dendritic cells (DCs) are essential mediators of productive immune responses to an infection and illness. NK cells and a subtype of DCs, the kind 1 standard DCs (cDC1s), are individually essential for regulating immune responses to most cancers in mice and people. Recent work has discovered that NK cells and cDC1s interact in intercellular cross-talk integral to initiating and coordinating adaptive immunity to most cancers. This NK cell-cDC1 axis has been linked to elevated total survival and responses to anti-PD-1 immunotherapy in metastatic melanoma sufferers. Here, we evaluation latest findings on the function of NK cells and cDC1s in protecting immune responses to most cancers and immunotherapy, in addition to present therapies concentrating on this NK cell-cDC1 axis.
Further, we discover the idea that intercellular cross-talk between NK cells and cDC1s could also be key for many of the optimistic prognostic associations seen with NK cells and DCs individually. It is evident that rising our understanding of the NK cell-cDC1 innate immune cell axis shall be essential for the era of novel therapies that may modulate anti-cancer immunity and improve affected person responses to frequent immunotherapies. In abstract, full phosphorylation of PKB at T308 and S473 by PDK1 and mTORC2 is important for optimum NK cell improvement, and PKB regulates NK cell improvement by selling E4BP4 expression and stopping cell apoptosis.
Updating targets for pure killer/T-cell lymphoma immunotherapy
Natural killer/T-cell lymphoma (NKTCL) is a extremely invasive subtype of non-Hodgkin lymphoma, usually optimistic for cytoplasmic CD3, CD56, cytotoxic markers, together with granzyme B and TIA1, and Epstein-Barr virus (EBV). The present remedy strategies for NKTCL are related to a number of drawbacks. For instance, chemotherapy can result in drug resistance, whereas remedy with radiotherapy alone is insufficient and leads to frequent relapses.
Moreover, hematopoietic stem cell transplantation reveals restricted efficacy and shouldn’t be effectively acknowledged by home and international specialists. In latest years, immunotherapy has proven good medical outcomes and has grow to be a scorching spot in most cancers analysis. Clinical exercise of focused antibodies, equivalent to daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL. Additionally, dacetuzumab and Campath-1H have demonstrated promising outcomes. Further encouraging knowledge have been obtained utilizing checkpoint inhibitors.
The success of these immunotherapy brokers is attributed to excessive expression ranges of programmed death-ligand 1 in NKTCL. Furthermore, anti-CCR4 monoclonal antibodies (mAbs) exert cytotoxic actions on each CCR4+ tumor cells and regulatory T cells. Depletion of these cells and the lengthy half-life of anti-CCR4 mAbs end in enhanced induction of antitumor effector T cells. The function of IL10 in NKTCL has additionally been investigated. It has been proposed that exploitation of this cytokine may present potential novel therapeutic methods.
Cellular immunotherapy with engineered cytotoxic T lymphocytes focused towards LMP1 and LMP2 has proven promising outcomes and sustained remission. Cellular immunotherapy could also be used both as upkeep remedy following preliminary induction chemotherapy or in instances of relapsed/refractory illness. The current evaluation outlines the recognized immunotherapy targets for the remedy of NKTCL. This enrichment has had substantial enter by inhabitants admixture with neighboring populations, who contributed HLA class I haplotypes expressing the KIR ligands B*46:01 and B*58:01, which subsequently rose to excessive frequency by pure choice.
Adaptive Admixture of HLA class I Allotypes Enhanced Genetically Determined Strength of Natural Killer Cells in East Asians
Human pure killer (NK) cells are important for controlling an infection, most cancers and fetal improvement. NK cell features are modulated by interactions between polymorphic inhibitory killer cell immunoglobulin-like receptors (KIR) and polymorphic HLA-A, -B and -C ligands expressed on tissue cells. All HLA-C alleles encode a KIR ligand and contribute to replica and immunity. In distinction, just some HLA-A and -B alleles encode KIR ligands and they give attention to immunity. By high-resolution evaluation of KIR and HLA-A, -B and -C genes, we present that the Chinese Southern Han are considerably enriched for interactions between inhibitory KIR and HLA-A and -B.
Alpha-bungarotoxin, CF640r |
|||
| 9-00004 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF488a |
|||
| 9-00005 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF568 |
|||
| 9-00006 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin CF594 |
|||
| 9-00007 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-bungarotoxin, CF633 |
|||
| 9-00009 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin |
|||
| 00010-1 | Biotium | 1MG | EUR 168 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Fluorescein-Alpha-bungarotoxin |
|||
| 00011 | Biotium | 500uG | EUR 367 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Tetramethylrhodamine-Alpha-bungarotoxin |
|||
| 00012 | Biotium | 500uG | EUR 383 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
| 00013 | Biotium | 10ST | EUR 417 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
| 00014 | Biotium | 10ST | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
| 00015 | Biotium | 500uG | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
| 00016 | Biotium | 10ST | EUR 523 |
|
Description: Minimum order quantity: 1 unit of 10ST |
|||
Biotin-xx-a-bungarotoxin |
|||
| 00017 | Biotium | 500uG | EUR 433 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Alpha-Bungarotoxin, CF555 conjugate |
|||
| 9-00018 | Biotium |
|
|
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Biotin-cAMP, diisopropylethylammonium salt: |
|||
| 00020 | Biotium | 1MG | EUR 314 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00020-1 | Biotium | 20ST | EUR 418 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Biotin-cGMP, diisopropylethylammonium salt: |
|||
| 00021 | Biotium | 1MG | EUR 344 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
| 00021-1 | Biotium | 20ST | EUR 448 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Cyanine 644-cAMP: |
|||
| 00022 | Biotium | 1MG | EUR 491 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Cyanine 644-cAMP: (20x50ug) |
|||
| 00022-1 | Biotium | 20ST | EUR 625 |
|
Description: Minimum order quantity: 1 unit of 20ST |
|||
Fluorescein Methotrexate, triammonium salt: |
|||
| 00023 | Biotium | 1MG | EUR 281 |
|
Description: Minimum order quantity: 1 unit of 1MG |
|||
Staurosporine |
|||
| 00025 | Biotium | 100uG | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 100uG |
|||
Alpha-bungarotoxin, CF543 |
|||
| 00026 | Biotium | 500uG | EUR 494 |
|
Description: Minimum order quantity: 1 unit of 500uG |
|||
Rhodamine phalloidin 300u |
|||
| 00027 | Biotium | 300 | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300 |
|||
Biotin-xx-phalloidin |
|||
| 00028 | Biotium | 100U | EUR 428 |
|
Description: Minimum order quantity: 1 unit of 100U |
|||
Fluorescein-phalloidin |
|||
| 00030 | Biotium | 300U | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Rhodamine 110 phalloidin |
|||
| 00032 | Biotium | 300ST | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300ST |
|||
Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
| 00033 | Biotium | 300EU | EUR 345 |
|
Description: Minimum order quantity: 1 unit of 300EU |
|||
Phalloidin, CF405M |
|||
| 00034 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF405M |
|||
| 00034-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
CF488A-cAMP |
|||
| 00036 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
CF640R-cAMP |
|||
| 00037 | Biotium | 100ug | EUR 172 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Phalloidin, CF555 |
|||
| 00040 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF555 |
|||
| 00040-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF647 |
|||
| 00041 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF647 |
|||
| 00041-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF488A |
|||
| 00042 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF488A |
|||
| 00042-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF543 |
|||
| 00043 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF543 |
|||
| 00043-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF568 |
|||
| 00044 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF568 |
|||
| 00044-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF594 |
|||
| 00045 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF594 |
|||
| 00045-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF633 |
|||
| 00046 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF633 |
|||
| 00046-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660R |
|||
| 00047 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660R |
|||
| 00047-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680R |
|||
| 00048 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680R |
|||
| 00048-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF350 |
|||
| 00049 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF350 |
|||
| 00049-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF640R |
|||
| 00050 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF640R |
|||
| 00050-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF532 |
|||
| 00051 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF532 |
|||
| 00051-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF660C |
|||
| 00052 | Biotium | 300U | EUR 442 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF660C |
|||
| 00052-T | Biotium | 50U | EUR 133 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF680 |
|||
| 00053 | Biotium | 300U | EUR 466 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF680 |
|||
| 00053-T | Biotium | 50U | EUR 147 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF430 |
|||
| 00054 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF430 |
|||
| 00054-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Phalloidin, CF440 |
|||
| 00055 | Biotium | 300U | EUR 449 |
|
Description: Minimum order quantity: 1 unit of 300U |
|||
Phalloidin, CF440 |
|||
| 00055-T | Biotium | 50U | EUR 139 |
|
Description: Minimum order quantity: 1 unit of 50U |
|||
Cholera Toxin Subunit B, CF488A conjugate |
|||
| 00070 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF568 conjugate |
|||
| 00071 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF594 conjugate |
|||
| 00072 | Biotium | 100ug | EUR 261 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF640R conjugate |
|||
| 00073 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF532 conjugate |
|||
| 00074 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF543 conjugate |
|||
| 00075 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF620R conjugate |
|||
| 00076 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF633 conjugate |
|||
| 00077 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF660R conjugate |
|||
| 00078 | Biotium | 100ug | EUR 264 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Cholera Toxin Subunit B, CF680R conjugate |
|||
| 00079 | Biotium | 100ug | EUR 282 |
|
Description: Minimum order quantity: 1 unit of 100ug |
|||
Human Transferrin, CF488A conjugate |
|||
| 00081 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF543 conjugate |
|||
| 00082 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF568 conjugate |
|||
| 00083 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF594 conjugate |
|||
| 00084 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF640R conjugate |
|||
| 00085 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF680R conjugate |
|||
| 00086 | Biotium | 1mg | EUR 149 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
Human Transferrin, CF750 conjugate |
|||
| 00087 | Biotium | 1mg | EUR 155 |
|
Description: Minimum order quantity: 1 unit of 1mg |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 tat recombinant antigen |
|||
| 00110-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 tat recombinant antigen full length 15 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 GAG P24 Recombinant Antigen |
|||
| 00111-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 nef recombinant antigen |
|||
| 00112-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-1 env gp41 recombinant antigen |
|||
| 00113-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HIV-2 GP 36 Recombinant Antigen |
|||
| 00114-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen |
|||
| 00115-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, Biotin conjugate |
|||
| 00115-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, FITC conjugate |
|||
| 00115-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV core recombinant antigen, Rhodamine |
|||
| 00115-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b |
|||
| 00116-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
| 00116-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, FITC |
|||
| 00116-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
| 00116-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HCV NS3 recombinant antigen |
|||
| 00117-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen |
|||
| 00120-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV core recombinant antigen, Delta |
|||
| 00121-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg |
|||
| 00122-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00123-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant High purity |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HBV surface recombinant antigen HBsAg antigen |
|||
| 00124-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HBV surface recombinant antigen HBsAg antigen 31 kDa E. coli recombinant |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00131-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 633 to a.a 659. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
HEV (Birma) ORF2 recombinant antigen |
|||
| 00132-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 403 to a.a 461. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
AA 403-461 HEV Birma ORF2 Recombinant Antigen |
|||
| 00133-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HEV (Birma) ORF2 recombinant antigen a.a. 92 to a.a 123. |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p15 |
|||
| 00141-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p15 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p17 |
|||
| 00142-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p17 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, Pallidum recombinant antigen p45 |
|||
| 00143-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen p45 (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
T, pallidum recombinant antigen TmpA |
|||
| 00144-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: T. Pallidum recombinant antigen TmpA (full length) |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV core 2-119aa recombinant antigen |
|||
| 00150-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core 2-119aa recombinant antigen. Genotypes available: 1a, 1b, 2a, 2b, 3a, 3b, 3/10, 4, 5, 6a |
|||
HCV Core 24 Antigen |
|||
| 00151-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core 24 antigen. |
|||
HCV Core 24 Antigen |
|||
| 00151-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core 24 antigen. |
|||
HCV core recombinant antigen |
|||
| 00152-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV core recombinant antigen |
|||
| 00152-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV core recombinant antigen a.a.105-302 |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1192-1456 aa Recombinant Antigen |
|||
| 00153-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 1192-1456aa recombinant antigen a.a.1192-1459. Available genotypes: 1a, 1b, 2b, 2c, 5, 6a |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS3 1359-1456aa antigen |
|||
| 00154-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS3 1359-1456aa antigen. The protein contains immunodominant regions (1359-1456aa). available genotypes: 1a, 1b, 2b, 3, 4, 5, 6 |
|||
HCV NS4 mosaic recombinant antigen |
|||
| 00155-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
|||
HCV NS4 mosaic recombinant antigen |
|||
| 00155-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 mosaic recombinant antigen a.a1691-1710, 1712-1733, 1921-1940. Genotypes available: 1, 2, 3, 5. |
|||
HCV NS4 1916-1947aa recombinant antigen |
|||
| 00156-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
|||
HCV NS4 1916-1947aa recombinant antigen |
|||
| 00156-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS4 1916-1947aa recombinant antigen. |
|||
HCV NS5 2061-2302aa recombinant antigen |
|||
| 00157-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS5 2061-2302aa recombinant antigen. |
|||
HCV NS5 2061-2302aa recombinant antigen |
|||
| 00157-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS5 2061-2302aa recombinant antigen. |
|||
HCV NS5 2212-2313aa recombinant antigen |
|||
| 00158-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
|||
HCV NS5 2212-2313aa recombinant antigen |
|||
| 00158-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
|
Description: HCV NS5 2212-2313aa recombinant antigen. Available genotypes: 1a, 1b, 2a, 2b, 3a, 3b, 4, 5, 6a. |
|||
HAV VP1-P2A recombinant antigen |
|||
| 00159-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
|
Description: HAV VP1-P2A recombinant antigen a.a. 722-830. |
|||
Consequently, over 80% of Southern Han HLA haplotypes encode a couple of KIR ligand. Complementing the excessive quantity of KIR ligands, the Chinese Southern Han KIR locus combines a excessive frequency of genes expressing potent inhibitory KIR, with a low frequency of these expressing activating KIR. The Southern Han centromeric KIR area encodes sturdy, conserved, inhibitory HLA-C particular receptors, and the telomeric area offers a excessive quantity and range of inhibitory HLA-A and -B particular receptors. In all these traits, the Chinese Southern Han signify different East Asians, whose NK cell repertoires are thus enhanced in amount, range and effector power, doubtless augmenting resistance to endemic viral infections.